{"id":"W2889005127","doi":"10.1200/jco.2013.31.15_suppl.8104","title":"A phase I/II trial combining erlotinib with gamma secretase inhibitor RO4929097 in advanced non-small cell lung cancer (NSCLC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Erlotinib; Clinical endpoint; Internal medicine; Lung cancer; Oncology; KRAS; Phases of clinical research; Chemotherapy; Cancer; Gastroenterology; Clinical trial; Epidermal growth factor receptor; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00122857,0.001448063,0.001781523,0.0004878513,0.0003963459,0.0008964236,0.0008909871,0.001537813,0.004867588],"category_scores_gemma":[0.0007218486,0.0005254453,0.0009500775,0.0003769709,0.0006749562,0.0009656796,0.0004019521,0.002288654,0.001578322],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009012921,"about_ca_system_score_gemma":0.00119512,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000891475,"about_ca_topic_score_gemma":0.002428129,"domain_scores_codex":[0.9996842,0.0001497878,0.00001995562,0.00004907184,0.00002460118,0.00007246719],"domain_scores_gemma":[0.9996171,0.00006227561,0.00007289233,0.00002722203,0.00002234543,0.0001980369],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8032863,0.04945143,0.005440949,0.001396959,0.00110283,0.0004243758,0.0001885437,0.002375518,0.0258785,0.0004024659,0.008447777,0.1016043],"study_design_scores_gemma":[0.7669126,0.2213574,0.00667525,0.00003752061,0.0002981289,0.0002517068,0.0000367498,0.0009708693,0.001154837,0.0001469262,0.002137308,0.00002072591],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9863282,0.002762911,0.0003974921,0.0009512478,0.0002303217,0.003950856,0.001637799,0.0001321951,0.003608999],"genre_scores_gemma":[0.9807915,0.002407877,0.001338084,0.001984567,0.0002622127,0.00407636,0.003985425,0.00003378835,0.005120187],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004867588,"threshold_uncertainty_score":0.01628369,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05083421285477605,"score_gpt":0.4696614283411989,"score_spread":0.4188272154864229,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}